New approach: boosting immune system to fight skin cancer before surgery
NCT ID NCT04315701
Summary
This study is testing whether giving an immunotherapy drug called cemiplimab before surgery helps treat a type of skin cancer called cutaneous squamous cell carcinoma. The drug aims to help the patient's own immune system attack the cancer and shrink the tumor, potentially making surgery more effective. The trial involves about 35 adults with high-risk, recurrent, or regionally advanced skin cancer that is still considered removable by surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT SKIN SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hoag Memorial Hospital
Newport Beach, California, 92663, United States
-
Los Angeles County-USC Medical Center
Los Angeles, California, 90033, United States
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
-
University of Nebraska
Omaha, Nebraska, 68198, United States
Conditions
Explore the condition pages connected to this study.